Disorders of sphingolipid metabolism and other lipid storage disorders

E4_SPHINGOLIP

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

None

520210

2. Check conditions

None

520210

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 E75
  • Cause of death: ICD-10 E75

2 out of 7 registries used, show all original rules.

-

4. Check minimum number of events

None

-

5. Include endpoints

128

6. Filter based on genotype QC (FinnGen only)

128

Control definitions (FinnGen only)

Control exclude
E4_METABOLIA

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
E70-E90
Name in latin
Perturbationes metabolismi sphingolipidorum et aliae perturbationes accumulationis lipidorum

Case counts by codes

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1246 706 535
Only index persons 803 474 329
Unadjusted period prevalence (%)
Whole population 0.02 0.02 0.01
Only index persons 0.02 0.02 0.01
Median age at first event (years)
Whole population 36.20 39.79 31.10
Only index persons 46.79 48.86 43.80

-FinnGen-

Key figures

All Female Male
Number of individuals 128 80 48
Unadjusted period prevalence (%) 0.02 0.03 0.02
Median age at first event (years) 54.70 53.33 57.00

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
119
Matched controls
1188
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E75.2
ICD-10 Finland
Other sphingolipidosis
+∞
64.6
56
*
E75.5
ICD-10 Finland
Other lipid storage disorders
+∞
21.5
20
*
N08.4*E75.2
ICD-10 Finland
Glomerular disorders in Fabry(-Anderson) disease
+∞
19.3
18
*
E75.6
ICD-10 Finland
Lipid storage disorder, unspecified
+∞
19.3
18
*
E78.5
ICD-10 Finland
Hyperlipidaemia, unspecified
21.8
17.9
26
15
N08.4
ICD-10 Finland
Glomerular disorders in other endocrine, nutritional and metabolic diseases
+∞
12.7
12
*
Z31.5
ICD-10 Finland
Genetic counselling
10.4
12.3
24
28
E78.01
ICD-10 Finland
Pure hypercholesterolaemia
7.4
12.1
30
52
ZX120
NOMESCO Finland
Intravenous
7.8
10.8
25
39
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
5.0
10.4
36
94
195
Kela drug reimbursment
Agalsidase alfa, agalsidase beta and migalastat
+∞
9.5
9
*
WX892
NOMESCO Finland
Monitored bed care
7.3
8.8
21
34
E75.0
ICD-10 Finland
GM2gangliosidosis
+∞
8.4
8
*
XF402
NOMESCO Finland
ECG with work load test
5.3
8.3
26
60
FM1DG
NOMESCO Finland
Very extensive MRI examination of heart with high intesity magnet
24.0
8.2
11
5
TPH04
NOMESCO Finland
Cathetrisation of vein
3.9
8.0
36
119
336
Kela drug reimbursment
Agalsidase alfa, agalsidase beta and migalastat
+∞
7.4
7
*
E75.3
ICD-10 Finland
Sphingolipidosis, unspecified
+∞
7.4
7
*
151
Kela drug reimbursment
Eliglustat, imiglucerase and velaglucerase alfa
+∞
7.4
7
*
B01AC04
ATC
clopidogrel; oral
5.0
7.2
23
54
XF404
NOMESCO Finland
Ambulatory ECG
5.2
6.9
21
47
E78.9
ICD-10 Finland
Disorder of lipoprotein metabolism, unspecified
42.5
6.8
8
*
E78.00
ICD-10 Finland
Familial hypercholesterolaemia
24.1
6.8
9
*
XF400
NOMESCO Finland
ECG with 12 standard connections
3.9
6.6
28
87
C10AA01
ATC
simvastatin; oral
2.8
6.6
58
303
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.7
6.4
59
315
XFE00
NOMESCO Finland
Epicardial ultrasonography
19.3
6.4
9
5
A16AB04
ATC
agalsidase beta; parenteral
+∞
6.3
6
*
333
Kela drug reimbursment
Eliglustat, imiglucerase and velaglucerase alfa
+∞
6.3
6
*
6AB04
NOMESCO Finland
NA
+∞
6.3
6
*
E75.4
ICD-10 Finland
Neuronal ceroid lipofuscinosis
+∞
6.3
6
*
E75.1
ICD-10 Finland
Other gangliosidosis
+∞
6.3
6
*
C10AX09
ATC
ezetimibe; oral
5.7
6.2
17
34
M04AA01
ATC
allopurinol; systemic
4.3
6.0
22
60

Mortality – FinRegistry

Association

Association between endpoint E4_SPHINGOLIP and mortality.

Females

Parameter HR [95% CI] p-value
E4_SPHINGOLIP 3.646 [2.73, 4.87] < 0.001
Birth year 0.999 [0.99, 1.01] 0.732

During the follow-up period (1.1.1998 — 31.12.2019), 168 out of 492 females with E4_SPHINGOLIP died.

Males

Parameter HR [95% CI] p-value
E4_SPHINGOLIP 3.928 [2.65, 5.83] < 0.001
Birth year 0.989 [0.98, 1.0] 0.021

During the follow-up period (1.1.1998 — 31.12.2019), 135 out of 358 males with E4_SPHINGOLIP died.

Mortality risk

Mortality risk for people of age

years, who have E4_SPHINGOLIP.

N-year risk Females Males
1 0.297% 0.842%
5 2.115% 4.462%
10 5.718% 11.325%
15 11.212% 20.673%
20 19.21% 34.437%

Relationships between endpoints

Index endpoint: E4_SPHINGOLIP – Disorders of sphingolipid metabolism and other lipid storage disorders

GWS hits: 3

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data